Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • Phathom Pharmaceuticals' Change in Accured Expenses fell 90.16% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 4.80%. This contributed to the annual value of $34.9 million for FY2024, which is 445.02% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Change in Accured Expenses stood at $1.1 million, which was down 91.00% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Change in Accured Expenses ranged from a high of $19.9 million in Q4 2024 and a low of -$11.3 million during Q1 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Change in Accured Expenses value was $4.6 million (recorded in 2023), while the average stood at $4.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 204.27% in 2024, then slumped by 90.16% in 2025.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Change in Accured Expenses stood at $3.9 million in 2022, then skyrocketed by 162.11% to $10.3 million in 2023, then soared by 94.24% to $19.9 million in 2024, then plummeted by 90.16% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to $12.4 million in Q2 2025 and -$7.0 million in Q1 2025.